Publicaciones en colaboración con investigadores/as de Université de Genève (13)

2020

  1. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

    The Lancet Neurology, Vol. 19, Núm. 11, pp. 951-962

  2. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 47, Núm. 8, pp. 1885-1912

  3. Proven validity and management impact of amyloid imaging in Alzheimer’s disease—repetita juvant

    European Journal of Nuclear Medicine and Molecular Imaging

2019

  1. Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC)

    NeuroImage: Clinical, Vol. 23

2018

  1. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus

    European Journal of Neurology, Vol. 25, Núm. 10, pp. 1201-1217

  2. Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1470-1486

  3. Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1557-1566

  4. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1534-1545

  5. Clinical utility of FDG-PET for the clinical diagnosis in MCI

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1497-1508

  6. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1509-1525

  7. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1546-1556

  8. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1487-1496

  9. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1526-1533